243 related articles for article (PubMed ID: 12171725)
1. CAMPATH-1H in the treatment of autoimmune cytopenias.
Marsh JC; Gordon-Smith EC
Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
[TBL] [Abstract][Full Text] [Related]
2. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Willis F; Marsh JC; Bevan DH; Killick SB; Lucas G; Griffiths R; Ouwehand W; Hale G; Waldmann H; Gordon-Smith EC
Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
[TBL] [Abstract][Full Text] [Related]
3. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Elimelakh M; Dayton V; Park KS; Gruessner AC; Sutherland D; Howe RB; Reding MT; Eastlund T; van Burik JA; Singleton TP; Gruessner RW; Key NS
Haematologica; 2007 Aug; 92(8):1029-36. PubMed ID: 17640860
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.
Rodon P; Breton P; Courouble G
Eur J Haematol; 2003 May; 70(5):319-21. PubMed ID: 12694169
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.
Reiff A; Shaham B; Weinberg KI; Crooks GM; Parkman R
J Clin Immunol; 2011 Aug; 31(4):615-22. PubMed ID: 21541793
[TBL] [Abstract][Full Text] [Related]
6. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of autoimmune cytopenias.
Robak T
Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
[TBL] [Abstract][Full Text] [Related]
8. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
9. The CD52 antigen and development of the CAMPATH antibodies.
Hale G
Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
[No Abstract] [Full Text] [Related]
10. Campath-1H therapy in refractory ocular inflammatory disease.
Dick AD; Meyer P; James T; Forrester JV; Hale G; Waldmann H; Isaacs JD
Br J Ophthalmol; 2000 Jan; 84(1):107-9. PubMed ID: 10611109
[TBL] [Abstract][Full Text] [Related]
11. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
12. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology.
Dungarwalla M; Marsh JC; Tooze JA; Lucas G; Ouwehand W; Pettengell R; Dearden CE; Gordon Smith EC; Elebute MO
Ann Hematol; 2007 Mar; 86(3):191-7. PubMed ID: 17123083
[TBL] [Abstract][Full Text] [Related]
13. A personal history of the CAMPATH-1H antibody.
Waldmann H
Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
[TBL] [Abstract][Full Text] [Related]
14. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Killick SB; Marsh JC; Hale G; Waldmann H; Kelly SJ; Gordon-Smith EC
Br J Haematol; 1997 May; 97(2):306-8. PubMed ID: 9163593
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
Walsh M; Chaudhry A; Jayne D
Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Moreton P; Hillmen P
Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab in stem cell transplantation.
Hale G
Med Oncol; 2002; 19 Suppl():S33-47. PubMed ID: 12180491
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
Diehl LF; Ketchum LH
Semin Oncol; 1998 Feb; 25(1):80-97. PubMed ID: 9482530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]